We have a technology that can potentially inactivate a class of pharmaceuticals. Pharmaceutical side-effects can have a detrimental effect on the health and wellbeing of individuals. Pharmaceutical companies can suffer significant monetary loss when drug candidates do not pass clinical trials. Given that the pharmaceutical industry is a multibillion-dollar industry, we believe there is significant interest in utilizing a technology that can control the activity of a pharmaceutical. We will use the Lab2Market initiative to learn start-up methodologies and take a scientific approach to entrepreneurship for our start-up company, AzoSolutions. We will continue primary market research and speak with stakeholders to validate or reject our hypothesis. We anticipate scaling up our product for commercialization and will learn to contact potential clients.